FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know

What happened: The FDA warned of a potential increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss, in patients taking GLP-1 RA medications. Why it matters: The label change affects all currently marketed GLP-1 RA products. The Sentinel study found increased risk versus DPP-4 inhibitors but no statistically significant increase versus SGLT-2 inhibitors. The FDA advises doctors to consider discontinuing treatment in patients who develop NAION unless benefits clearly outweigh risks. Coverage: 5 outlets in 24h

The FDA warned of a potential increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss, in patients taking GLP-1 RA medications.

The label change affects all currently marketed GLP-1 RA products. The Sentinel study found increased risk versus DPP-4 inhibitors but no statistically significant increase versus SGLT-2 inhibitors. The FDA advises doctors to consider discontinuing treatment in patients who develop NAION unless benefits clearly outweigh risks.